Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial

Trial Profile

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2018

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jun 2018 Planned initiation date changed from 2 May 2018 to 2 Jul 2018.
    • 16 Apr 2018 Planned initiation date changed from 2 Apr 2018 to 2 May 2018.
    • 29 Mar 2018 Planned initiation date changed from 26 Mar 2018 to 2 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top